The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma (Q38950690)

7 September 2017

The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma (English)

1 reference

7 September 2017

4

David L Bartlett

1 reference

7 September 2017

6

Herbert J Zeh

1 reference

7 September 2017

Aatur D Singhi

1

1 reference

7 September 2017

Alyssa M Krasinskas

2

1 reference

7 September 2017

Haroon A Choudry

3

1 reference

7 September 2017

James F Pingpank

5

1 reference

7 September 2017

Alyssa Luvison

7

1 reference

7 September 2017

Kimberly Fuhrer

8

1 reference

7 September 2017

Nathan Bahary

9

1 reference

7 September 2017

Raja R Seethala

10

1 reference

7 September 2017

Sanja Dacic

11

1 reference

7 September 2017

23 October 2015

1 reference

7 September 2017

1 reference

7 September 2017

29

1 reference

7 September 2017

1

1 reference

7 September 2017

14-24

1 reference

https://scigraph.springernature.com/pub.10.1038/modpathol.2015.121

7 September 2017

0 references

cites work

Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.121

Current concepts: malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.121

Early peritoneal mesothelioma: a treatable malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.121

Management of peritoneal-surface malignancy: the surgeon's role

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.121

A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.121

Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.121

Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.121

Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.121

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.121

A review of peritoneal mesothelioma at the Washington Cancer Institute

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.121

Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.121

The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.121

High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.121

High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.121

Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.121

Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.121

Frequent p16 inactivation by homozygous deletion or methylation is associated with a poor prognosis in Japanese patients with pleural mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.121

Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.121

Functional inactivation of NF2/merlin in human mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.121

The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.121

Hemizygosity of Nf2 is associated with increased susceptibility to asbestos-induced peritoneal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.121

BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.121

Loss of expression of BAP1 predicts longer survival in mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.121

Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.121

CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.121

A new standard of care for the management of peritoneal surface malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.121

FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.121

p16 Deletion in sarcomatoid tumors of the lung and pleura.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.121

Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.121

Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.121

A conditional mouse model for malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.121

Consensus statement on peritoneal mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.121

A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.121

Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.121

Malignant peritoneal mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.121

Peritoneal mesothelioma: a review

21 January 2018

1 reference

12 December 2020

1 reference

12 December 2020

Peritoneal mesothelioma

1 reference

12 December 2020

Prospective trial for the treatment of malignant peritoneal mesothelioma

1 reference

12 December 2020

Clinical presentation of peritoneal mesothelioma

1 reference

12 December 2020

p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma

1 reference

12 December 2020

Malignant pleural mesothelioma

1 reference

12 December 2020

Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas.

1 reference

12 December 2020

Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors

1 reference

12 December 2020

Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis.

1 reference

12 December 2020

Prognostic Analysis of Clinicopathologic Factors in 49 Patients With Diffuse Malignant Peritoneal Mesothelioma Treated With Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion

1 reference

12 December 2020

10.1038/MODPATHOL.2015.121

Identifiers

DOI

1 reference

Dimensions Publication ID

7 September 2017

0 references

1 reference